Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
02/29/2024
Portfolio News
New
Proceeds to be used to complete clinical proof-of-concept trial for lead candidate, RNDP-001, for the treatment of Parkinson’s disease.
Saisei Ventures Invests in United Immunity, Co., Ltd., to Develop New Cancer Immune-Therapeutics Using Proprietary Immune Cell-Selective Delivery Technology
09/11/2023
Portfolio News
Saisei Ventures is pleased to announce a new investment in United Immunity, a biotechnology company developing proprietary tumor-associated-macrophage-selective nanoparticles.
Saisei Ventures is Selected as a Certified VC Fund by AMED to Catalyze the Japanese Drug Development Ecosystem
05/17/2023
Saisei News
Saisei Ventures is one of nine VC firms accredited by AMED for funding as part of its Drug Discovery Venture Ecosystem Enhancement Project.